-
放疗是鼻咽癌的首选治疗方法,鼻咽癌常规放疗后约超过10%的患者有鼻咽部肿瘤残留,对于残留肿瘤组织及时追加照射剂量是改善局部控制率和总生存率的有效方法,而且一次性放疗治愈鼻咽癌可显著提高患者的生存质量,第2疗程放疗患者大多并发严重的后遗症。20世纪90年代中期以来,适形放射治疗(conformal radiotherapy,CRT)成为鼻咽癌常规放疗最主要的方式。调强放射治疗(intensity modulation radiation therapy,IMRT)是近年来发展并逐渐成熟的放疗新技术。IMRT技术可调节每个照射野内不同位置的射线强度,使不同照射野的剂量分布不均匀,从而对不同照射野的放射剂量进行非常精确地控制,实现差异化照射。IMRT技术通过改善靶区剂量分布提高疗效,同时通过显著降低靶区外正常组织及重要器官的照射剂量,减少不良反应及后遗症的发生。与传统的鼻咽癌放疗技术相比,IMRT技术在剂量学上优势明显,且目前国内大多数肿瘤中心均采用高于常规分割的剂量给予方式,这些差异均可使放疗后PET/CT显像早期疗效评估存在差异。本研究旨在探讨鼻咽癌在CRT和IMRT不同模式放疗后一周PET/CT早期评估的价值。
鼻咽癌不同模式放疗后的PET/CT早期评估价值的研究
Early evaluation value of PET/CT in nasopharyngeal carcinoma after different models of radiotherapy
-
摘要:
目的 研究鼻咽癌在适形放疗(CRT)和调强放疗(IMRT)不同模式放疗后1周18F-FDG PET/CT显像早期评估的价值。 方法 对CRT组21例及IMRT组19例患者放疗后1周进行PET/CT显像评估,分别进行目测分析及测量最大标准化摄取值(SUVmax),并与两年临床随访结果及病理活检结果进行对照。 结果 CRT组患者2年临床随访无肿瘤残留,IMRT组17例患者活检结果无残留、2例活检结果为阳性;放疗前PET/CT显像CRT组与IMRT组的SUVmax分别为9.57±4.33、9.40±3.32,两组间差异无统计学意义(t=-0.43,P=0.132);放疗后CRT组与IMRT活检阴性组的SUVmax分别为2.38±0.34、3.10±0.55,两组间差异有统计学意义(t=-3.4,P=0.002)。CRT组目测诊断准确率为76.2%,目测假阳性率为23.8%;IMRT组目测诊断准确率为63.2%,目测假阳性率为36.8%。 结论 放疗后1周作为18F-FDG PET/CT对鼻咽癌CRT后评估时间点是可行的;放疗后1周IMRT组的SUVmax较高,不是PET/CT的最佳评估时间点。 -
关键词:
- 鼻咽肿瘤 /
- 正电子发射断层显像术 /
- 放射疗法,适形 /
- 放射疗法,调强适形
Abstract:Objective To study the early evaluation value of 18F-FDG PET/CT imaging in nasopharyngeal carcinoma on the 7-day after different models of radiotherapy, including conformal radiotherapy(CRT) and intensity-modulated radiotherapy(IMRT). Methods PET/CT imaging was performed in 21 cases of CRT group and 19 cases of IMRT group on the 7-day after radiotherapy. The visual examination was performed and the maximum standardized uptake value(SUVmax) was measured, and the results were compared with the two years clinical follow-up and the result of pathological biopsy. Results Two years clinical follow-up of the CRT group confirmed there was no residual tumor. There was no residual tumor in 17 cases and 2 cases were positive of the IMRT group confirmed by biopsy. The SUVmax of the CRT group and the IMRT group were 9.57±4.33 and 9.40±3.32 respectively before radiotherapy without significant difference(t=-0.43, P=0.132). SUVmax of the CRT group and the negative patients confirmed by biopsy of the IMRT group were 2.38±0.34 and 3.1±0.55 respectively after radiotherapy with significant difference (t=-3.4, P=0.002). The accuracy rate and the false positive rate of visual examination of the CRT group were 76.2% and 23.8% respectively. The accuracy rate and the false positive rate of visual examination of the IMRT group were 63.2% and 36.8% respectively. Conclusion s One week after nasopharyngeal carcinoma CRT is the feasible time-point for 18F-FDG PET/CT assessment. SUVmax of the IMRT group on 7-day after radiotherapy was higher than that in CRT group, so this time-point is not the best evaluation time-point of the PET/CT. -
-
[1] 孔琳, Nancy Y.鼻咽癌调强放射治疗进展[J].中国癌症杂志, 2008, 18(9): 672-676. doi: 10.3969/j.issn.1007-3639.2008.09.008
[2] 王颖, 冯彦林. 18F-FDG-PET/CT在鼻咽癌靶区勾画及推量照射中的研究进展[J].国际放射医学核医学杂志, 2011, 35(2): 84-88. doi: 10.3760/cma.j.issn.1673-4114.2011.02.005
[3] 罗耀武, 唐安戊, 朱永钳, 等. 18F-FDG PET显像诊断鼻咽癌放疗后病灶残留或复发[J].中华核医学杂志, 2005, 25(5): 303.
[4] 黎功, 郑静晨, 于金明, 等. 18F-FDG PET评价鼻咽癌放疗疗效[J].中华核医学杂志, 2007, 27(2): 102. doi: 10.3760/cma.j.issn.2095-2848.2007.02.017
[5] 冯彦林, 冼伟均, 袁建伟, 等.鼻咽癌Ki67表达与放疗前后18F-FDG PET-CT显像相关性的动物模型及临床研究[J].肿瘤防治研究, 2011, 38(10): 1133-1136. doi: 10.3971/j.issn.1000-8578.2011.10.010
[6] 袁建伟, 冯彦林, 冼伟均, 等.利用18F-FDG PET-CT显像监测裸鼠鼻咽癌移植瘤早期放疗疗效的研究[J].癌症, 2010, 29(4): 409-414. doi: 10.3969/j.issn.1001-5930.2010.04.029
[7] Wu VW, Kwong DL, Sham JS. Target dose conformity in 3-dimensional conformal radiotherapy and intensity modulated radiotherapy[J]. Radiother Oncol, 2004, 71(2): 201-206. [8] Kam MK, Teo PM, Chau RM, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience[J]. Int J Radiat Oncol Biol Phys, 2004, 60(5): 1440-1450. doi: 10.1016/j.ijrobp.2004.05.022